A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes

BACKGROUND: Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16%...

Descripción completa

Detalles Bibliográficos
Autores principales: Vakrakou, A. G., Tzanetakos, D., Valsami, S., Grigoriou, E., Psarra, K., Tzartos, J., Anagnostouli, M., Andreadou, E., Evangelopoulos, M. E., Koutsis, G., Chrysovitsanou, C., Gialafos, E., Dimitrakopoulos, A., Stefanis, L., Kilidireas, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206708/
https://www.ncbi.nlm.nih.gov/pubmed/30373566
http://dx.doi.org/10.1186/s12883-018-1183-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206708/
https://www.ncbi.nlm.nih.gov/pubmed/30373566
http://dx.doi.org/10.1186/s12883-018-1183-4

Ejemplares similares